Was Hormel's Q2 Earnings Report the Turnaround Investors Needed?

Patient through the SPAM maker's painful slide from a $45 stock to the low $20s. Patient through missed earnings quarters, goodwill write-downs, and a turkey business that seemed to generate nothing but headaches.